XM no presta servicios a los residentes de Estados Unidos de América.
G
G

Gerresheimer


Noticias

Adidas, Spirax Group, Stroeer

EUROPE RESEARCH ROUNDUP-Adidas, Spirax Group, Stroeer July 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas, Spirax Group and Stroeer, on Wednesday. HIGHLIGHTS * Adidas AG ADSGn.DE : JP Morgan raises target price to EUR 260 from EUR 250 * J D Wetherspoon JDW.L : Jefferies raises target price to 1,000p from 925p * Spirax Group SPX.L : HSBC raises to hold from reduce * Stroeer SAXG.DE : HSBC raises target price to EUR 79 fro
A
A
A
A
A
B
B
C
D
D
E
E
E
F
F
G
R
S
S
U
A
A
E
E
R
S
U

Hargreaves Lansdown, Spectris, Wizz Air

EUROPE RESEARCH ROUNDUP-Hargreaves Lansdown, Spectris, Wizz Air July 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Hargreaves Lansdown, Spectris and Wizz Air, on Friday. HIGHLIGHTS * Hargreaves Lansdown HRGV.L : JP Morgan raises target price to 684p from 671p * Spectris Plc SXS.L : Jefferies cuts target price to 4190p from 4435p * Spirax-Sarco SPX.L : Jefferies cuts target price to 9580p from 9690p * Weir Group WEIR.L : Jefferi
A
A
B
B
B
C
C
D
E
E
E
E
E
G
H
H
I
L
L
M
R
R
S
S
W
A
D

Gerresheimer Exec On Conference Call - Estimate Revenue Growth To Be Around Lower End Of Our Guidance Range For 2024

BRIEF-Gerresheimer Exec On Conference Call - Estimate Revenue Growth To Be Around Lower End Of Our Guidance Range For 2024 July 11 (Reuters) - GERRESHEIMER AG GXIG.DE : EXEC ON CONFERENCE CALL - ESTIMATE REVENUE GROWTH TO BE AROUND LOWER END OF OUR GUIDANCE RANGE FOR 2024 Further company coverage: GXIG.DE (Gdansk Newsroom)
G

Gerresheimer up as guidance confirmation reassures, analysts say

BUZZ-Gerresheimer up as guidance confirmation reassures, analysts say ** Shares in Gerresheimer GXIG.DE rise around 2% in early Frankfurt trade after the German medical packaging devices maker reported a small earnings beat and stuck to its FY guidance ** "Good enough," J.P.Morgan says on the Q2 results, pointing to adjusted EBITDA coming in 2.5% a
G

Gerresheimer's weight-loss drug deals pipeline helps profits meet forecasts

UPDATE 2-Gerresheimer's weight-loss drug deals pipeline helps profits meet forecasts Adds guidance in paragraph 4, CEO comment in paragraph 3-5, analyst comment in paragraph 6 By Isabel Demetz July 11 (Reuters) - Medical equipment group Gerresheimer GXIG.DE posted second-quarter adjusted core profit in line with expectations on Thursday, driven by the deal pipeline for its plastics and devices business, which supplies weight-loss drug makers with autoinjector pens.
G

Gerresheimer's second-quarter results in line with expectations

Gerresheimer's second-quarter results in line with expectations July 11 (Reuters) - German packaging and medical equipment maker Gerresheimer GXIG.DE reported second-quarter core profit in line with market expectations on Thursday. Negative destocking effects in its primary packaging glass division were offset by the good performance of its plastics and devices division, it said.
G

Gerresheimer confirms 2024 guidance

BRIEF-Gerresheimer confirms 2024 guidance July 11 (Reuters) - Gerresheimer AG GXIG.DE : GERRESHEIMER AG - GERRESHEIMER REMAINS ON TRACK IN 1ST HALF YEAR 2024 GERRESHEIMER AG - ORGANIC GROWTH: REVENUES +1.7%, ADJUSTED EBITDA +2.9% GERRESHEIMER AG - PLASTICS & DEVICES DIVISION WITH GOOD REVENUE GROWTH AND SIGNIFICANTLY IMPROVED MARGIN GERRESHEIMER AG
G

Europe's STOXX 600 corporate earnings week ahead

DIARY-Europe's STOXX 600 corporate earnings week ahead July 5 (Reuters) - Diary of Europe's STOXX 600 (.STOXX) corporate earnings for the week ahead EUROPE'S STOXX 600 EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 08-Jul-2024 NTS INDUa.ST Industrivarden AB Q2 2024 Industrivarden AB Earnings Release 08-Jul-2024 05:30 WIHL.ST Wihlborgs Fastigheter AB Q2 2024 Wihlborgs Fastigheter AB Earnings Release 09-Jul-2024 06:00 KINVb.ST Kinnevik AB Q2 2024 Kinnevik AB Earnings Release 10-J
E
E
G
I
K
S

Obesity drug injections maker Gerresheimer expands capacity in US

Obesity drug injections maker Gerresheimer expands capacity in US May 27 (Reuters) - German drug vial maker Gerresheimer GXIG.DE on Monday announced an expansion of its U.S. production site as it sees growing demand for weight-loss drugs, including of the GLP-1 class. The company is investing around 166 million euros ($180.24 million) in the construction of two buildings, creating 400 new jobs in Peachtree.
G

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Thyssenkrupp, Hg, Hess Corp, Millicom International Cellular May 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday: * * Thyssenkrupp TKAG.DE said its supervisory board approved a planned sale of 20% of the conglomerate's steel division to Czech billionaire Daniel Kretinsky in the face of continued opposition from labour representatives.
C
G
H
T
A

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Updates: May 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Thursday: ** Nationwide Building Society NBS.L said it could realise as much as a 1.5 billion pound ($1.91 billion) gain on its acquisition of rival Virgin Money, announced earlier this year and expected to close in the fourth quarter.
G
H
A

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions May 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Thursday: ** Nationwide Building Society NBS.L said it could realise as much as a 1.5 billion pound ($1.91 billion) gain on its acquisition of rival Virgin Money, announced earlier this year and expected to close in the fourth quarter.
G
H
A

Gerresheimer shares shine on deal to buy Blitz LuxCo Sarl

BUZZ-Gerresheimer shares shine on deal to buy Blitz LuxCo Sarl ** Shares in Gerresheimer GXIG.DE jump 12.1% after the German medical equipment maker said it had signed a purchase agreement to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group for 800 million euros ($865.92 million) ** The transaction will be financed by a consortium of banks consisting of UniCredit, Commerzbank CBKG.DE and LBBW and is expected to close in Q4, according to the statement ** "We expect the m
C
G
U

Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln

UPDATE 1-Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln Adds details in paragraphs 2 and 3 and background in 4 and 5 May 23 (Reuters) - German packaging and medical equipment maker Gerresheimer GXIG.DE said on Thursday it signed a purchase agreement for acquiring Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group, for an enterprise value of 800 million euros ($866.32 million).
C
G
U

Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln

Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln May 23 (Reuters) - German packaging and medical equipment maker Gerresheimer GXIG.DE said on Thursday it signed a purchase agreement for acquiring Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group, for an enterprise value of 800 million euros ($866.32 million). ($1 = 0.9234
G

Gerresheimer Says To Acquire Blitz Luxco Sarl, The Holding Company Of The Bormioli Pharma Group

BRIEF-Gerresheimer Says To Acquire Blitz Luxco Sarl, The Holding Company Of The Bormioli Pharma Group May 23 (Reuters) - Gerresheimer AG GXIG.DE : EQS-ADHOC: GERRESHEIMER TO ACQUIRE BLITZ LUXCO SARL, THE HOLDING COMPANY OF THE BORMIOLI PHARMA GROUP / MOULDED GLASS BUSINESS TO BE STRATEGICALLY REVIEWED PURCHASE PRICE IS BASED ON A DETERMINED ENTERPR
G

UBS starts Gerresheimer with 'buy' on 1 exposure

BUZZ-UBS starts Gerresheimer with 'buy' on GLP-1 exposure ** UBS initiates Gerresheimer GXIG.DE with "buy," as it sees the German medical packaging supplier as an attractive play on GLP-1 class of diabetes and weight-loss drugs ** The brokerage highlights Gerresheimer's exposure to all relevant players and optionality stemming from CagriSema, one o
G

Alfa Laval, OMV AG, Unilever Plc

EUROPE RESEARCH ROUNDUP- Alfa Laval, OMV AG, Unilever Plc May 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alfa Laval, OMV AG and Unilever Plc, on Tuesday. HIGHLIGHTS * Alfa Laval ALFA.ST : JP Morgan raises target price to SEK 385 from SEK 325 * Babcock International BAB.L : Citigroup raises target price to 640p from 530p * OMV AG OMVV.VI : Morgan Stanley raises to equal weight from underweight * SKAN Group AG SKAN.S : Baader
A
A
A
B
C
C
D
F
G
H
I
I
I
L
M
O
O
P
S
S
S
T
A
B
B
D
J
P



Condiciones

Activos populares

Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.

Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.

Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.

Advertencia de riesgo: Su capital está en riesgo. Los productos apalancados pueden no ser adecuados para todos. Por favor, tenga en cuenta nuestra Declaración de riesgos.